In the same vein, the RCT: NCT02222207, where regorafenib was used as a topical treatment to inhibit VEGF activity in wet AMD, was terminated after phase IIa, because of its lower efficacy compared to current wet AMD treatments [221]. Here, VEGFA is linked to wet macular degeneration.